Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT07513285 · Acurx Pharmaceuticals Inc.

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

What this study is about

Single-treatment group$1 trial to evaluate the safety and effectiveness of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

View original scientific description

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Interventions

DRUG

Ibezapolstat

Ibezapolstat 450 mg po Q12H x14 days

Primary outcome measures

Evaluate the rate of CDI Clinical Cure (CC)

Time frame: Day 16

Evaluate the rate of Sustained Clinical Cure (SCC)

Time frame: Day 42

Evaluate the rate of CDI recurrence (rCDI)

Time frame: Day 70

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins
  • Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.
  • At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin

Exclusion criteria

  • Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure \< 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon
  • Received more than 24 hours of dosing with antibiotics for the current CDI episode:
  • Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks
  • Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin \[IVIG\], bezlotoxumab
  • Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms \> 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.
  • Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.
  • Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks
  • Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).
  • Known current history of a severely compromised immune system

Where

  • Sacramento, California
  • Hamden, Connecticut
  • Coral Gables, Florida
  • Hialeah, Florida
  • Miami Lakes, Florida
  • Miami Springs, Florida
  • Athens, Georgia
  • Idaho Falls, Idaho
  • Skokie, Illinois
  • Newton, Massachusetts
  • Worcester, Massachusetts
  • Detroit, Michigan

And 3 more locations — see the full list below.

Related conditions & keywords

Clostridium Difficile Infection RecurrenceClostridioides difficileCdiffRecurrent Clostridioides difficile

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Aug 12, 2026 · Source of record for eligibility and locations

📊
1 of 20 participants interested
5% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

NOT_YET_RECRUITING

Sacramento

California

Location available
NOT_YET_RECRUITING

Hamden

Connecticut

Location available
NOT_YET_RECRUITING

Coral Gables

Florida

Location available
RECRUITING

Hialeah

Florida

Location available
NOT_YET_RECRUITING

Miami Lakes

Florida

Location available
NOT_YET_RECRUITING

Miami Springs

Florida

Location available
NOT_YET_RECRUITING

Athens

Georgia

Location available
RECRUITING

Idaho Falls

Idaho

Location available
NOT_YET_RECRUITING

Skokie

Illinois

Location available

And 6 more locations available.

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Clostridioides Difficile Infection Trials by City

Browse all clostridioides difficile infection clinical trials in these cities — not just this study.

Looking for Clostridium Difficile Infection Recurrence Treatment in Sacramento?

Join others in California exploring innovative treatment options through clinical research

Clostridium Difficile Infection Recurrence Treatment Options in Sacramento, California

If you're searching for Clostridium Difficile Infection Recurrence treatment in Sacramento, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Sacramento, Hamden, Coral Gables and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Clostridium Difficile Infection Recurrence. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 20 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Clostridium Difficile Infection Recurrence?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Clostridium Difficile Infection Recurrence

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Clostridium Difficile Infection Recurrence Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT07513285. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.